CRAIGAVON pharmaceutical giant Almac Group has pledged to be net zero by 2045 and has also committed to reduce its Scope one and Scope two emissions by 50 per cent by 2030.
It coincide with the release of its 2022 corporate social responsibility (CSR) report, which highlights the group’s ongoing commitment to their people, the planet and the communities in which they operate.
Within the report, Almac details actions already taken to address energy use, including the accreditation of UK and Ireland sites to the international standard for energy management, ISO 50001. A future commitment was also made to roll it out to US and APAC sites in the coming years.
The company has also included a commitment in the report that all new building projects at Almac Group campuses globally will be designed and constructed to Building Research Establishment Environmental Assessment Method (BREEAM) standards (or appropriate global equivalent).
“As a global leader in providing a range of expert services and support across the drug development life cycle, it is crucial that we demonstrate our commitment to the long-term sustainability of the sector,” Almac executive director Niall Harkin said.
“I'm hugely encouraged by the progress that we have made this year as detailed in this report and very proud of the environmental commitments we announce today.”
Almac's chief executive Alan Armstrong added: “We are proud to publish our corporate social responsibility report for 2022, which details our commitment to our people, our planet, and the communities in which we operate.
“The report outlines excellent progress in these focus areas, and looking forward, we will continue to introduce new initiatives to deliver our future ambitions.”
